Pathos
PrivateLast Round
Series E
Aug 4, 2026
Est. Valuation
$3B
Total Funding Raised
$467M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Pathos is a clinical-stage biotechnology company that utilizes an AI-enabled drug discovery platform to accelerate the development of precision oncology therapeutics.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Foundation
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Pathos Comparables
Compare Pathos with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Valo Health | 83% | |
| Insilico Medicine | 81% | |
| Insitro | 81% | |
Pathos Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | Aug 4, 2026 | ||||
| Series D | May 15, 2025 | ||||
| Series C | Oct 29, 2024 | ||||
| Series B | Mar 2, 2023 | ||||
| Series A | Jul 1, 2021 |
Key People
Founding team and executive leadership
Pathos Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Builders VC | Series C, Series B, Series A |
| Lightbank | Series C, Series B, Series A |
| New Enterprise Associates (NEA) | Series B, Series A, Series C |
| Revolution Ventures | Series C |
| Revolution Growth | Series C, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 4, 2026
$300M round at $3B valuation.
- Apr 1, 2026
AI drug development platform Foundry is now live and in production.
Pathos Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Pathos's valuation, stock price, and market status.